Allergic Rhinitis Treatment Market, By Treatment Type (Immunotherapy (SCIT, SLITD, SLITT), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids), By Route of Administration (Oral, Nasal, Intraocular, Intravenous), By Distribut

Allergic Rhinitis Treatment Market, By Treatment Type (Immunotherapy (SCIT, SLITD, SLITT), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids), By Route of Administration (Oral, Nasal, Intraocular, Intravenous), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Allergic rhinitis or hay fever is an IgE-mediated disorder caused by allergens such as mold or tress, animal, dander, house dust mites, weed pollens, and grass. It can occur in two different forms namely, seasonal and perennial, which in turn causes mild or moderate to severe inflammation inside the nose. Some of the major symptoms of allergic rhinitis include nasal congestion, rhinorrhea, sneezing, nasal itching, and itchy eyes, or it can be associated with asthma as well. Allergic rhinitis and sinusitis are linked to each other, as allergic rhinitis blocks the nose, which in turn blocks the sinuses. In 2015, according to World Allergy Organization, over 400 million people suffered from allergic rhinitis worldwide. Moreover, in the U.S., 10-30% adults and around 40% children were affected by allergic rhinitis.
Restraints of the Global Allergic Rhinitis Treatment Market
Major factors hampering the growth of the allergic rhinitis treatment market during the forecast period constitutes of absence of disease curing treatment, and similarity of symptoms with other diseases.
Key features of the study:
This report provides in-depth analysis of the global allergic rhinitis treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global allergic rhinitis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global allergic rhinitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Allergic Rhinitis Treatment Market, By Treatment Type:
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
Global Allergic Rhinitis Treatment Market, By Route of Administration:
Oral
Nasal
Intraocular
Intravenous
Global Allergic Rhinitis Treatment Market, By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
E-commerce
Global Allergic Rhinitis Treatment Market, By Geography:
North America
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country:
U.S.
Canada
Europe
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Immunotherapy
SCIT
SLITD
SLITT
Anti-histamines
Decongestants
Leukotriene Receptor Antagonists
Corticosteroids
By Route of Administration
Oral
Nasal
Intraocular
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
E-commerce
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Merck & Co., Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Boehringer Ingelheim
AstraZeneca Plc
GlaxoSmithKline PLC
Sanofi S.A.
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Alcon (Novartis AG)
Unichem Laboratories
Mylan
Innovus Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
“*” marked represents similar segmentation in other categories in the respective section.